Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Necrotizing enterocolitis (NEC) is a severe gastrointestinal disease affecting mainly preterm newborns. It is characterized by unexpected onset and rapid progression with specific diagnostic signs as or gas in the portal vein appearing later in the course of the disease. Therefore, we analyzed diagnostic and prognostic potential of the markers of early NEC pathogenesis, such as excessive inflammatory response (serum amyloid A (SAA)) and gut epithelium damage (intestinal and liver fatty acid-binding protein (I-FABP and L-FABP, respectively) and trefoil factor-3 (TFF-3)). We used ELISA to analyze these biomarkers in the urine of patients with suspected NEC, either spontaneous or surgery-related, or in infants without gut surgery (controls). Next, we compared their levels with the type of the disease (NEC or sepsis) and its severity. Already at the time of NEC suspicion, infants who developed NEC had significantly higher levels of all tested biomarkers than controls and higher levels of I-FABP and L-FABP than those who will later develop sepsis. Infants who will develop surgery-related NEC had higher levels of I-FABP and L-FABP than those who will develop sepsis already during the first 6 hours after the abdominal surgery. I-FABP was able to discriminate between infants who will develop NEC or sepsis and the SAA was able to discriminate between medical and surgical NEC. Moreover, the combination of TFF-3 with I-FABP and SAA could predict , and the combination of I-FABP, L-FABP, and SAA could predict gas in the portal vein or long-term hospitalization and low SAA predicts early full enteral feeding. Thus, these biomarkers may be useful not only in the early, noninvasive diagnostics but also in the subsequent NEC management.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7072107PMC
http://dx.doi.org/10.1155/2020/3074313DOI Listing

Publication Analysis

Top Keywords

i-fabp l-fabp
20
will develop
16
higher levels
12
nec
10
necrotizing enterocolitis
8
gas portal
8
portal vein
8
nec sepsis
8
nec higher
8
levels i-fabp
8

Similar Publications

Perfluorooctanesulfonate (PFOS) is a persistent environmental pollutant in the per- and polyfluoroalkyl substances (PFAS) class, known to accumulate in the liver and trigger hepatotoxicity. While studies suggested that fatty acid-binding proteins (FABPs) drive the hepatic accumulation of PFAS, evidence is entirely lacking. Using wild-type and mice with global deletion of liver-type and intestine-type FABP (L-FABP, I-FABP), we measured PFOS toxicokinetics by administering single oral doses (0.

View Article and Find Full Text PDF

Until recently, it was believed that bacterial translocation occurs as a result of leaky gut syndrome or sepsis. To confirm or exclude the process of bacterial translocation, biomarkers can be used. One such biomarker is defensins, which indicate immune activity, as defensins are cationic peptides with antibacterial properties produced by intestinal epithelial cells.

View Article and Find Full Text PDF

Background And Aims: Portal hypertension, gut barrier dysfunction, and pathological bacterial translocation are hallmarks of cirrhosis driving complications. As measuring gut barrier function is demanding, surrogate markers have been proposed, but their intercorrelation and applicability across different stages of advanced liver disease, particularly in acute-on-chronic liver failure (ACLF), are largely unknown.

Methods: Proposed markers of gut barrier dysfunction and bacterial translocation were quantified in sera from 160 patients with cirrhosis across different disease stages of compensated and decompensated cirrhosis as well as from 20 patients in hepatic and portal vein serum before and after the insertion of transjugular intrahepatic portosystemic stent (TIPS) using enzyme-linked immunosorbent assay (ELISA).

View Article and Find Full Text PDF
Article Synopsis
  • Individuals with long-term type 1 diabetes may have an increased risk of heart issues due to inflammation caused by gut microbiota entering the bloodstream, leading to atherosclerosis.
  • A study involving 102 people with type 1 diabetes and 63 controls measured several biomarkers related to gut inflammation and assessed coronary atherosclerosis using advanced imaging techniques.
  • The results indicated that higher levels of intestinal fatty acid binding protein (I-FABP) were linked to significant coronary artery blockages, suggesting it could be a potential marker for heart disease in diabetes patients.
View Article and Find Full Text PDF

Precision medicine in intestinal ischemia: the emerging role of biomarkers.

Intern Emerg Med

March 2025

First Clinic of Internal Medicine, Department of Internal Medicine, University of Genoa, 6 Viale Benedetto XV, 16132, Genoa, Italy.

Intestinal ischemia (IIs) is a significant gastrointestinal condition characterized by reduced blood flow to the bowel, leading to inflammation and injury. Early diagnosis and management are crucial for preventing severe complications. Under this point of view, circulating biomarkers can enhance patient stratification and guide therapeutic decisions.

View Article and Find Full Text PDF